BioSpace News Archive

The report offers details about market revenue growth, market size, drivers, restraints, limitations, growth opportunities and top companies.

The latest market report presented by Reports and Data, titled “Burn Care Market Size, Share And Industry Analysis By Product Type (Advanced Burn Care Products, Biologics, Traditional Burn Care Products, and Others), By Depth of Burn, By Cause (Thermal Burn, Electrical Burn, Radiation Burn, Chemical Burn, and Friction Burn), By End-Use, and By Region Forecast to 2028,” is inclusive of crucial data & information pertaining to the global Burn Care market.

The latest market report presented by Reports and Data, titled “Sodium Hyaluronate Eye Drops Market, By Treatment Type (Dry Eye Disease, Sjogren’s Syndrome, Stevens-Johnson Syndrome, Conjunctival, Corneal Epithelial Injuries), By Distribution Channel (E-commerce, Pharmacies), and By Region Forecast to 2028,” is inclusive of crucial data & information pertaining to the global Sodium Hyaluronate Eye Drops market.

Reports and Data has recently added a research report on Temporary Pacemaker Market By Product Type (Single Chamber Pacemaker, Dual Chamber Pacemaker, Triple Chamber Pacemaker), By End-use (Hospitals, Specialty Clinics, Others), and By Region Forecast to 2028. The report offers detailed overview of the market with recent market dynamics and industrial status.

Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $1.95 per share on its outstanding shares of Common Stock.

ASC Therapeutics has joined as a full partner the Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC) including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), managed by the Foundation for the National Institutes of Health (FNIH).

Neurocrine Biosciences, Inc. announced that it has entered into separate, privately negotiated transactions with certain holders of its existing 2.25% Convertible Senior Notes due 2024 to repurchase approximately $179.4 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of an amount of cash estimated to be the sum of approximately $224.0 million, an amount based in part on the trading price of the Company’s common stock and accrued and unpaid interest.

Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum).

Chinook Therapeutics, Inc. announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share.

Genexine announced that Neil Warma, CEO of Genexine will be presenting virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.